BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series.

Abstract excerpt

The management of cancer has been traditionally dependent on the primary tumour type and specific histologic subtypes. Recently, the introduction of molecular profiling tools and its increasing use in clinical practice has facilitated the emergence of novel genomically driven treatment options within the standard of care landscape as well as in the clinical trial setting. One such aberration is mutation in v-Raf...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aged
• Share to Antineoplastic Combined Chemotherapy Protocols